The link tells us that Dupilumab may now be marketed to the 12 - 17 year age group in the EC.
(Note that BTX 1204 Phase 2 trial is for the 12 years to 70 years age group.)
Dupilumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.
Administered by injection.
Adverse reactions include conjunctivitis and injection site reactions (around 10% for each).
IMO, apart possibly from severe asthma sufferers, if BTX 1204 is successful in the Phase 2 trial it will go on to be the first line of attack against moderate atopic dermatitis.
The link tells us that Dupilumab may now be marketed to the 12 -...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.010(2.82%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.3¢ | 34.5¢ | $582.2K | 1.679M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32454 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 210000 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |